


PHARMACEUTICAL 2023

AYTU BIOPHARMA INC Rank 324 of 446







PHARMACEUTICAL 2023

AYTU BIOPHARMA INC Rank 324 of 446



The relative strengths and weaknesses of AYTU BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AYTU BIOPHARMA INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 117% points. The greatest weakness of AYTU BIOPHARMA INC is the variable Assets, Current, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is -27%, being 70% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	59,929
Cost of Goods Sold	44,386
Intangible Assets	70,632
Liabilities, Current	64,442
Liabilities, Non-Current	12,810
Other Assets	7,062
Other Compr. Net Income	0
Other Expenses	118,128
Other Liabilities	14,279
Other Net Income	1,278
Other Revenues	96,669
Property and Equipment	0
Research and Development	14,439
Selling, General and Administrative Expense	31,167

Output Variable	Value in 1000 USD
Assets	137,623
Liabilities	91,531
Expenses	208,120
Revenues	96,669
Stockholders Equity	46,092
Net Income	-110,173
Comprehensive Net Income	-110,173
Economic Capital Ratio	-27%

